Kaletra in Combination With Antiretroviral Agents
Kaletra in Combination With Antiretroviral Agents
The purpose of this study is to investigate the tolerability of Kaletra (lopinavir/ritonavir)
 in combination with new substances such as integrase inhibitors (INIs), C-C chemokine
 receptor type 5 (CCR5) antagonists, and new non-nucleoside reverse transcriptase inhibitors
 (NNRTIs), as there are many reasons (intolerability, complex resistant patterns or even
 personal reasons) which may result in a change from the daily clinical routine and lead to
 the use of a newly approved antiretroviral agent in combination with Kaletra.
This study was designed as a non-interventional observational study. Kaletra was prescribed
 in the usual manner in accordance with the terms of the local market authorization with
 regards to dose, population and indication as well as local guidelines.
Inclusion Criteria:

 -  Patients ≥ 18years of age

 -  Written informed consent (authorization to the investigator to use and/or disclose
 personal and/or health data before entry into the KALETRA® post marketing
 observational study)

 -  HIV-1 infection

 -  Patients treated with KALETRA®, independent from their participation in this study

 -  Patients treated with novel antiretroviral therapy (for at least 8 weeks according to
 the study amendment), independent from their participation in this study

 Exclusion Criteria:

 -  Hypersensitivity against Kaletra or other ingredients or INIs or NNRTIs or CCR5
 antagonists

 -  Severe liver insufficiency

 -  No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride,
 pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine,
 vardenafil and/or St. John's wort